N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 7, 2007, Pages 440-444

  Ekstein, Sivan ^a   Nir, Amiram ^b   Rein, Azaria J J T ^a   Perles, Zeev ^a   Bar Oz, Benjamin ^a   Salpeter, Lea ^a   Algur, Nurit ^b   Weintraub, Michael ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Anthracyclines; Cardiotoxicity; Chemotherapy; Natriuretic peptides; Pediatric oncology

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE DERIVATIVE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE TOXICITY; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; ECHOCARDIOGRAPHY; EWING SARCOMA; FEMALE; FOLLOW UP; HUMAN; INFANT; KIDNEY TUMOR; MALE; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN BLOOD LEVEL; RHABDOID TUMOR;

ADOLESCENT; ADULT; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; FEMALE; HEART; HUMANS; INFANT; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 34347373513     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3180640d42     Document Type: Article

References (23)

1. Gurney JG, Bondy ML. Epidemiology of childhood cancer. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott Williams & Wilkins; 2006: 1-13.
2. Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention - review of the literature. Med Sci Monit. 2000;6:411-420.
3. Doroshow J. Anthracyclines and anthracenediones. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy. Philadelphia: Lippincot Williams & Wilkins; 2001:500-523.
4. Legha SS, Benjamin RB, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133-139.
5. Von Hoff D, Rozencweig M, Layard M, et al. Daunomycin-induced cardiotoxicity in children and adults. Am J Med. 1977;62:200-208.
6. Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long term follow-up study. J Clin Oncol. 2001;19:191-196.
7. Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15:1544-1552.
8. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16:545-550.
9. Lipshultz SE, Colan SD, Gelber R, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808-815.
10. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900-905.
11. Poutanen T, Tikanoja T, Riikonen P, et al. Long-term prospective follow up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol. 2003;21:2349-2356.
12. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577-585.
13. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-328.
14. Mir TS, Marohn S, Laer S, et al. Plasma concentration of N terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics. 2002;110:76-86.
15. Baughman KL. B-type natriuretic peptide - a window to the heart. N Engl J Med. 2002;347:158-159.
16. Okumura H, Iuchi K, Yoshida T, et al. Brain natriuretic peptide is a predictor of anthracyclines-induced cardiotoxicity. Acta Haematol. 2000;104:158-163.
17. Suzuki T, Hayashi D, Yamazaki T, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J. 1998;136:362-363.
18. Hayakawa H, Komada Y, Hirayama M, et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol. 2001;37:4-9.
19. Nir A, Bar-Oz B, Perles Z, et al. N-terminal pro-B type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in heart diseases. Acta Paediatr. 2004;93:603-607.
20. Kawamura T, Wago M, Kawaguchi H, et al. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int. 2000;42:241-248.
21. Nousiainen T, Jantunen E, Vanninen E, et al. Acute neurohormonal and cardiovascular effect of idarubicin on leukemic patients. Eur J Haematol. 1998;61:347-353.
22. Kismet E, Varan A, Ayabakan C, et al. M serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer. 2004;42:220-224.
23. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145-153.